title: Re: Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2.
authors.forename: M Pilar
authors.initials: MP
authors.lastname: Laguna
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics*; D000970:Antineoplastic Agents / Q000191:economics*; D002292:Carcinoma, Renal Cell / Q000191:economics*; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007155:Immunologic Factors / Q000191:economics*; D007680:Kidney Neoplasms / Q000191:economics*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000191:economics*; D012042:Registries
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D047428:Protein Kinase Inhibitors